Community-acquired pneumonia (CAP)
Conditions
Interventions
CAP group:none
Sponsors
Huadu District Peoples Hospital of Guangzhou
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Inclusion Criteria for the Viral or Bacterial Pneumonia Patient Group Patients who meet all of the following criteria are eligible for inclusion in the study: (1) Diagnosed with community-acquired pneumonia (CAP) of viral or bacterial etiology according to the diagnostic criteria outlined in the Clinical Practice Guideline for Emergency Adult Community-Acquired Pneumonia (2024 Edition). (2) Aged between 18 and 75 years. (3) Time since symptom onset is within 72 hours. (4) Has provided written informed consent and voluntarily agrees to participate in the study. 2. Inclusion Criteria for the Non-infected Study Participant Group Individuals who meet all of the following criteria are eligible for inclusion in the study: (1) Aged between 18 and 75 years. (2) No acute infectious diseases (including, but not limited to, respiratory, gastrointestinal, or urinary tract infections) within the past 4 weeks. (3) No known chronic active inflammatory diseases or autoimmune diseases. (4) No recent vaccination (e.g., within the past 3 months), or a clear vaccination history without significant adverse reactions (further specification can be applied if needed). (5) Assessed by the investigator as being in generally stable condition and able to comply with the study procedures. (6) Capable of understanding the study content, voluntarily agrees to participate, and provides written informed consent. (7) Scheduled to undergo bronchoscopy for clinical reasons (e.g., pulmonary nodules), with the decision regarding lavage made clinically, and agrees to the use of any residual Bronchoalveolar Lavage Fluid (BALF) remaining after clinical testing/treatment (if available).
Exclusion criteria
Exclusion criteria: Patients meeting any of the following criteria should be excluded: 1. Other pulmonary diseases interfering with assessment: active tuberculosis, pulmonary fibrosis, lung cancer, lung abscess, non-infectious interstitial lung disease, pulmonary embolism, etc.; life-threatening non-pneumonia pulmonary diseases requiring immediate intervention. 2. Severe underlying diseases or comorbidities: (1) Presence of severe immunodeficiency diseases (such as active AIDS, leukemia, neutropenia, etc.), or currently receiving high-dose immunosuppressive therapy (such as chemotherapy, post-organ transplant anti-rejection therapy, long-term oral corticosteroid doses equivalent to prednisone >= 20 mg/day for more than 2 weeks); (2) Severe liver dysfunction (such as Child-Pugh class C or acute liver failure); (3) Severe renal insufficiency (glomerular filtration rate < 30 mL/min/1.73 m^2 or receiving renal replacement therapy); (4) Congestive heart failure with New York Heart Association (NYHA) functional class III-IV; (5) Uncontrolled arrhythmia or history of acute myocardial infarction within the past 6 months; (6) Patients with advanced malignant tumors with an expected survival of less than 3 months. 3. Study-related treatment and exposures: (1) Systemic (oral or intravenous) effective antibacterial therapy for more than 24 hours within 72 hours prior to admission; (2) Known or highly suspected severe allergy to antibacterial drugs and their excipients intended for use in the study protocol. 4. Special circumstances: (1) Pregnant or breastfeeding women; (2) Gastrointestinal diseases that may significantly affect drug absorption, distribution, metabolism, or excretion (such as active ulcerative colitis, intestinal obstruction, etc.); (3) Presence of mental illness, cognitive impairment, or any other reason that prevents understanding of the study, compliance with the treatment regimen, and follow-up requirements; (4) Any other medical or psychosocial factors that the investigator deems unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| General Characteristics of Antibody Molecular Structure and Its Post-translational Modification Patterns; | — |
Countries
China
Contacts
Public ContactLi jiashun
Huadu District Peoples Hospital of Guangzhou
Outcome results
None listed